TransMedics (TMDX) revenue breakdown
By product, Cost of net product revenue is the largest at 62% of fiscal 2025 revenue; Cost of service revenue grew fastest, 236% a year over 5 years.
By region, United States is the largest at 90% of fiscal 2022 revenue, growing 89% a year over 4 years.
Revenue by product
Fiscal years, as TransMedics reports them in its 10-K filings; fiscal 2025 total $605M.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Cost of net product revenue | — | — | $25M | $30M | $79M | $176M | $274M | $372M | 62% |
| Cost of service revenue | — | — | $547,000 | $605,000 | $14M | $66M | $168M | $233M | 38% |
| OCS Heart net revenue | $6M | $11M | — | — | — | — | — | — | — |
| OCS Lung net revenue | $5M | $9M | — | — | — | — | — | — | — |
| OCS Liver net revenue | $2M | $3M | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as TransMedics reports them in its 10-K filings; fiscal 2022 total $93M.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | Share |
|---|---|---|---|---|---|---|
| United States | $7M | $16M | $19M | $22M | $84M | 90% |
| All Other Countries | $2M | $7M | $6M | $8M | $9M | 10% |
| UNITED KINGDOM | $3M | — | — | — | — | — |
| GERMANY | $1M | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TMDX.
Open TMDX in InvestinglyQuestions
Where does TransMedics make its money?
In fiscal 2025, by product: Cost of net product revenue $372M, Cost of service revenue $233M.
From TransMedics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.